Retatrutide (30 mg Vial) Dosage Protocol

Research guide for gradual escalation dosing and reconstitution procedures for Retatrutide, a novel triple agonist investigated for substantial weight loss and metabolic improvement.

Dosing & Reconstitution Guide

Standard Gradual Titration for weekly subcutaneous administration

Weekly Subcutaneous Protocol (3 mL = 10.0 mg/mL)

Timeframe	Weekly Dose	Units (U-100)	mL Equivalent
Weeks 1–4	2,000 mcg (2 mg)	20 units	0.20 mL
Weeks 5–8	4,000 mcg (4 mg)	40 units	0.40 mL
Weeks 9–12	8,000 mcg (8 mg)	80 units	0.80 mL
Weeks 13+	12,000 mcg (12 mg)	120 units	1.20 mL*

Administration: Once weekly, subcutaneous injection. *At 12 mg maintenance, either split into two 0.60 mL injections or use a second vial.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe
2. Inject slowly down the vial wall; avoid foaming
3. Gently swirl/roll until dissolved (do not shake vigorously)
4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light

Result: 10.0 mg/mL concentration (30 mg vial ÷ 3.0 mL = convenient weekly measuring)

Storage Guidelines

• Lyophilized: −20 °C (−4 °F), dry/dark conditions
• Reconstituted: 2–8 °C (35.6–46.4 °F); do NOT freeze
• Shelf life: 28 days post-reconstitution

Key Administration Notes

• Rotate injection sites to prevent lipohypertrophy
• Gastrointestinal effects common initially; titration minimizes them
• Document weekly dose, date, and injection site
• Use sterile syringes; dispose in sharps container
• Allow vials to reach room temperature before opening